How do I know it is time to review the plan?
It may be time to review your plan when any of these things happen: Evidence Evidence
- You reach the review point you agreed on.
- Your skin seems to change.
- Your progress does not match the goal.
- You have a reaction.
- The routine is too hard to sustain.
- Your access to care changes.
- Your priorities change.
Why this item matters
- Sources cited, not yet graded
I read the task force recommendations for what a vitiligo decision is built around. The list is clinical pattern and activity, body site, prior care, health context, your goals, burden, and follow-up. Revisiting a choice is part of shared decision-making rather than proof that you did something wrong.
Check before moving on
- Depends on you
A photograph or missed record cannot establish treatment failure. How urgent it is, and what comes next, depend on what changed and on the exact treatment.
Questions for your treatment review
Which part of our original goal are we reviewing now?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What finding would make us continue, change, pause, or stop?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What should I bring to make the review useful?
Bring the treatment record you actually have. Include what you used, skipped, or held. Add changes, reactions, new areas, access problems, and comparable photos when available. An incomplete record is more useful than false certainty from memory. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
I would bring consistently framed photographs and dated observations, because they support a clinical conversation. Treatment burden, life impact, and practical barriers also belong beside visible skin change.
Check before moving on
- Depends on you
Your own photographs are not clinical scoring or proof of causation. Differences in lighting, distance, angle, clothing, or camera processing can create apparent change.
Questions for your treatment review
Which records are most useful for this decision?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What should I keep tracking differently before the next follow-up?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Before your next visit
Write down what to bring
Fill this in as you go, or the night before. Print it, or read it straight off your screen at the appointment.
Note ready.
When should I switch from a topical treatment to narrowband UVB?
I looked for a calendar or a result that tells everyone to switch, and there is none. Compare the current goal and evidence with body-area expectations, daily effort, risks, and access. Ask whether light would replace the exact cream or be coordinated with it. Evidence Evidence Evidence
Why this item matters
- Sources cited, not yet graded
Readers often ask whether a cream and light together beat either one alone. The guidelines I read include topical and light-based options, and support individualized, shared decisions. Selected combinations have evidence, but that does not create a general sequence for every medicine or patch.
Check before moving on
- Depends on you
Your clinician must judge whether the current trial was adequate and interpret the response. They must also align the exact medicine label with the light plan before any combination.
Questions for your treatment review
What evidence supports continuing, adding light, or changing paths?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What happens to my topical if narrowband UVB starts?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Do burden, cost, mood, and daily life count as reasons to change course?
Yes, they belong in the decision even when a treatment makes medical sense. A plan may stop fitting your life. Travel, time, privacy, cost, discomfort, uncertainty, emotional strain, and daily work can all change the balance. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The guidelines I read recognize quality of life and your priorities as part of treatment choice. Choosing a lower-burden path, camouflage, support, or no active treatment can be a deliberate decision.
Check before moving on
- Depends on you
No burden score can make the decision for you, and distress does not prove a treatment is ineffective. Support can be useful whether or not the medical plan changes.
Questions for your treatment review
Can we compare likely benefit with the real burden for me?
Saving keeps this on your device and needs JavaScript, which is off in this browser.What lower-burden or supportive options could still meet my priorities?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
What if I have a reaction, a new medicine, or a health change?
Record what happened and contact the responsible clinical team using their plan. Do not adjust a prescription or light setting without their instructions. New medicines, pregnancy, illness, eye concerns, or changing reactions may require a fresh safety review. Evidence Evidence
Why this item matters
- Sources cited, not yet graded
The prescription labels and phototherapy guidance I read carry treatment-specific warnings and precautions. Coordinated review matters when more than one clinician or treatment is involved.
Check before moving on
- Depends on you
Timing alone does not prove that treatment caused a reaction. Emergency symptoms need local emergency care.
Questions for your treatment review
Who is responsible for reconciling all of my medicines and light treatment?
Saving keeps this on your device and needs JavaScript, which is off in this browser.Which changes need a message, prompt call, or urgent care?
Saving keeps this on your device and needs JavaScript, which is off in this browser.
Applicability check
Who was studied?
These fields show what the cited evidence reports about the people and body sites behind outcome or safety claims. “Not reported” means the reviewed source omitted the field; “Pending exact source review” means SteadySkin has not made that determination yet.
Record what happened and contact the responsible clinical team using their plan. Do not adjust a prescription or light setting without their instructions. New medicines, pregnancy, illness, eye concerns, or changing reactions may require a fresh safety review.
- Age range
- Pending exact source review
- Condition subtype
- Pending exact source review
- Severity or extent
- Pending exact source review
- Sample size
- Pending exact source review
- Geography and care setting
- Pending exact source review
- Skin tone or phototype
- Pending exact source review
- Race
- Pending exact source review
- Ethnicity
- Pending exact source review
- Body sites
- Pending exact source review
What that means for this page: This is explicitly gated as a safety claim, but exact population extraction is still pending. It cannot publish or support an estimate of individual risk until that review is complete.
Evidence behind this page
Sources
Each evidence badge opens the source and its limits. The full list stays available here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
Supports an expert-consensus map of established, off-label and developing Vitiligo treatment categories and makes clear that research is continuing.
What it does not support
It is an international consensus with extensive author relationships, not independent comparative proof, current U.S. regulatory status for every option or a personal treatment sequence.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- JAMA Dermatology (Ezzedine K, et al.)Observational study · Supporting research, tier 3Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports defined research use and psychometric evaluation of facial and total VASI measures and the need to interpret score change in the studied context.
What it does not support
The analysis used sponsor trial data and included AbbVie authors; it does not establish one personally meaningful outcome, validate untrained home scoring or provide a treatment-change rule.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- DailyMed, U.S. National Library of MedicineRegulatory · Regulatory / guideline, tier 1Independence not established
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the defined US nonsegmental-vitiligo indication, limitations of use, boxed warnings, skin-cancer and ultraviolet precautions, and clinical-study labeling.
What it does not support
It also supports the labeled dosing instruction: "Apply a thin layer of OPZELURA topically twice daily to affected areas of up to 10% body surface area." It further supports the labeled re-evaluation point: "If the patient does not find the repigmentation meaningful by 24 weeks, the patient should be re-evaluated by the healthcare provider." It also supports the vitiligo-trial adverse-reaction rates at 1% incidence or greater: application-site acne 6%, application-site itching 5%, a common-cold-type illness (nasopharyngitis) 4%, headache 4%, urinary tract infection 2%, application-site redness (erythema) 2%, and fever (pyrexia) 1%. It does not guarantee benefit, establish suitability beyond the labeled population, authorize adding phototherapy, or state which reaction should prompt a call to the prescriber beyond directing patients to the Medication Guide and their healthcare provider.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Thomas KS, et al.)Randomized trial · Clinical research, tier 2Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports a group-level benefit for the exact supervised topical-corticosteroid and home handheld-light combination studied in active limited vitiligo, alongside minority success, reactions and limited maintenance after treatment ended.
What it does not support
It does not create a general home plan, support other product-device combinations or predict an individual result. The topical-corticosteroid-alone arm used mometasone furoate 0.1% ointment, applied once daily on alternating weeks for up to 9 months. It supports 17% (20/119) reaching participant-reported treatment success at 9 months, and 3% (4/115) reaching the trial’s stricter blinded-assessed ≥75% repigmentation at 9 months. Skin thinning was reported in 2.5% (13/517) of participants across all trial groups, including one on placebo ointment. Over 40% of participants across all groups reported loss of treatment response by 21 months. It supports that participant-reported treatment success at 9 months was lower for patches on the hands and feet than on other body regions, without publishing an exact per-region percentage in its main results tables. The trial randomized 517 adults and children, aged over 5, with nonsegmental vitiligo covering about 10% or less of body surface area and at least one patch active in the prior 12 months, across 16 UK hospitals.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- Journal of the European Academy of Dermatology and VenereologyGuideline · Regulatory / guideline, tier 1Relevant relationship disclosed
- Published
- SteadySkin last checked
What this source can and cannot tell you
Why the independence label says this: The journal is the publisher. This label refers to extensive author relationships disclosed for the recommendation, not to the journal itself.
What this source supports
It supports current expert-consensus terminology, clinical assessment, disease-activity evaluation, treatment-goal discussion, and shared decision-making. Its modified assessment check list names where the patches are as a disease feature, and gives genital involvement as its own example. It records white hairs as an item of its own, apart from what the vitiligo has done in the past six months. Its classification table keeps mucosal vitiligo as a subtype, both across more than one site and at one site alone. It supports planning care around what is there to work with, and its example is hair that still has its color. It names stable vitiligo and active vitiligo as two different states that change the care plan. Its shared-decision steps ask what the patient wants from care. At the time it was written, one cream form of a newer drug type had just been approved. Pill forms of that same drug type were still being studied.
What it does not support
It is not independent comparative proof. It cannot diagnose a reader from a description or photograph. It gives no figure for genital involvement, and it does not name lichen sclerosus. It does not set out the Vitiligo European Task Force grading scale. It puts no figure on white hairs and predicts nothing for one person.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Eleftheriadou V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
Supports the clinical history and assessment domains, evaluation of associated autoimmune conditions, its recommendation for thyroid function and antithyroid antibody screening, current classification context, treatment-option map, psychosocial assessment, medical photography and the limits of pediatric evidence. Its classification table defines mucosal vitiligo as the oral or genital mucosae. One mucosal site alone is filed as undetermined or unclassified. Its differential diagnosis table lists genital or extragenital lichen sclerosus among the conditions that can be mistaken for vitiligo. That table also lists eczema, psoriasis, lichen planus, pityriasis alba and piebaldism. It calls autoimmunity a contributor to the pathogenesis of vitiligo. It reports an earlier review finding a possible negative impact on intimacy and sexual functioning. It tells clinicians to discuss the psychosocial impact of living with the condition. R28 offers a skin camouflage visit to people who want one. R10 to R14 name potent or very potent topical steroids as the first choice, with a topical calcineurin-inhibitor cream as an option for the face. These are different creams with different proof behind them. R20 names narrowband UVB as the first light option. It says the skin often does better on the face and trunk than on hands and feet. It says there is not enough proof to use any one current pill alone for vitiligo that is not changing. R25 and Table 2 keep cell grafting for vitiligo that is not changing and did not respond to other care. They also say a doctor cannot always tell if the vitiligo has truly stopped changing.
What it does not support
It was designed for UK care and reviewed literature through May 2019; it does not establish a universal testing plan, prescribe an individual plan, or establish current US labeling or coverage. Its differential diagnosis table is a list, not a method a reader can apply to their own skin. It does not say how to tell any two of those conditions apart. It gives no figure for how often vitiligo affects genital skin.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.
- British Journal of Dermatology (Goulden V, et al.)Guideline · Regulatory / guideline, tier 1Independent source
- Published
- SteadySkin last checked
What this source can and cannot tell you
What this source supports
It supports that traditional NB-UVB fluorescent lamps emit a narrow UVB band peaking around 311 nanometres. It backs wearing UV-protective goggles and keeping UV scatter off people nearby. It records the consent form naming goggles and the same clothing at each session. It also covers clinical uses, how it compares with other light treatments, safety limits including sunburn-type reactions, and the added safeguards home phototherapy needs.
What it does not support
It does not provide a personal treatment plan, approve a particular home setup, or replace the instructions for your own device. SteadySkin never reproduces its treatment schedules.
Claim-specific review for this source is still in progress. Only the source-level evidence and limits are shown here.